Emergent BioSolutions (NYSE: EBS) reported Q2 EPS of $0.36, $0.18 better than the analyst estimate of $0.18. Revenue for the quarter came in at $126.1 million versus the consensus estimate of $114.25 million.

Emergent BioSolutions reaffirmed FY2015 guidance.

For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.